Search

This study aimed to explore the interactions among genetic determinants influencing ciprofloxacin resistance in Salmonella. Treatment with PAβN, an efflux pump inhibitor, resulted in a 4–32-fold reduction in the minimum inhibitory concentration (MIC) across all 18 ciprofloxacin-resistant Salmonella isolates. Notably, isolates without point mutations reverted from resistance to sensitivity. The efflux pump played a crucial role in resistance development, particularly in serovar Enteritidis, where PAβN treatment caused a more significant MIC reduction (16–32-fold) in five strains carrying the GyrA (Asp87Tyr) mutation, which initially exhibited high MICs (8 μg/mL). Several resistance genes were identified on transferable plasmids: oqxAB and aac(6′)-Ib-cr were associated with IncF plasmids in S. Enteritidis, IncA/C plasmids in S. Typhimurium, and IncHI2 plasmids in S. Virchow. Additionally, qnrS1 and/or qepA were carried by IncA/C plasmids in S. Thompson. Whole-genome sequencing revealed the presence of an oqxAB module integrated into the chromosomal DNA of S. Derby. Although the MICs of ciprofloxacin in transconjugants and transformants remained low (1–4 μg/mL), they exceeded the clinical breakpoint for susceptibility. These findings highlight the synergistic impact of efflux pumps and plasmid-mediated resistance mechanisms, contributing to the increasing prevalence of ciprofloxacin resistance and posing a significant threat to food safety. [ABSTRACT FROM AUTHOR]

As an effective method for uncertain knowledge discovery and decision-making, the three-way decisions model has attracted extensive attention from scholars. However, in practice, the existing sequential three-way decision model often faces challenges due to factors such as missing data and unbalanced attribute granularity. To address these issues, we propose an intuitionistic fuzzy sequential three-way decision (IFSTWD) model, which introduces several significant contributions: (1) New intuitionistic fuzzy similarity relations. By integrating possibility theory, our model defines similarity and dissimilarity in incomplete information systems, establishing new intuitionistic fuzzy similarity relations and their cut relations. (2) Granulation method innovation. We propose a density neighborhood-based granulation method to partition decision attributes and introduce a novel criterion for evaluating attribute importance. (3) Enhanced decision process. By incorporating sequential three-way decision theory and developing a multi-level granularity structure, our model replaces the traditional equivalent relation in the decision-theoretic rough sets model, thus advancing the model's applicability and effectiveness. The practical utility of our model is demonstrated through an example analysis of "Chinese + vocational skills" talent competency and validated through simulation experiments on the UCI dataset, showing superior performance compared to existing methods. [ABSTRACT FROM AUTHOR]

This document is a summary of a special issue of the journal Foods titled "Foodborne Pathogenic Bacteria: Prevalence and Control." The issue contains research articles and reviews on topics related to the detection, prevalence, growth, survival, and control of foodborne pathogenic bacteria. It covers various aspects such as rapid detection methods, antimicrobial resistance, biofilm formation, stress adaptation, and control strategies. The articles provide insights into the challenges of ensuring food safety and offer potential solutions to prevent and control the contamination of pathogenic bacteria in the food system. [Extracted from the article]

In order to analyze the interference mechanisms of indirect lightning effects on a low-noise amplifier (LNA), a circuit model of the LNA was constructed based on the advanced design system 2020 (ADS 2020) software. Lightning pulse injection simulations were conducted to explore the influence of lightning pulses on the performance of the LNA. A pin injection test was performed to investigate the interference and damage threshold of the LNA. A protective circuit incorporating the transient voltage suppressor (TVS) and Darlington structure was designed through simulation, employing the ADS 2020 for the LNA. The research findings reveal that the interference threshold for the LNA is 60 V, while the damage threshold is determined to be 100 V. The protective circuit demonstrates a measured insertion loss of 0.1 dB, a response time of 1.5 ns, and a peak output voltage of 20 V. The research results indicate that the protective circuit can effectively reduce the impact of lightning's indirect effects on the LNA. In the future, we will continue the design work of the protective circuit and proceed with physical fabrication and experimental validation. [ABSTRACT FROM AUTHOR]

Introduction: Durvalumab is a check‐point inhibitor against programmed death ligand‐1 (PD‐L1), and anlotinib is a new orally administered multitarget tyrosine kinase inhibitor (TKI). Both agents have been approved in China. Preclinical and clinical trials have suggested that antiangiogenic therapy has the potential to alleviate immunosuppression and showed synergetic effect when combined with ICIs. However, it is unclear that whether this combination is effective when initiated as maintenance treatment in ES‐SCLC patients. Methods: This is a multicenter, randomized, phase II study. A total of 64 eligible patients who do not experience disease progression after four cycles platinum‐based chemotherapy combined with durvalumab will be randomized to durvalumab with anlotinib or durvalumab alone until disease progression, withdrawal of consent, or unacceptable toxicity. The primary endpoint is PFS (from randomization); secondary endpoint was OS and PFS (from diagnosis), objective response rate (ORR); disease control rate (DCR) and duration of response (DOR), safety and tolerability assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Discussion: We conduct a phase II study to investigate the safety and efficacy of durvalumab combined with anlotinib as maintenance treatment in ES‐SCLC patients. [ABSTRACT FROM AUTHOR]